Check-Cap (NASDAQ:CHEK) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a report issued on Sunday morning. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

NASDAQ CHEK opened at $0.76 on Friday. The company has a market cap of $4.45 million, a P/E ratio of -0.25 and a beta of 0.39. Check-Cap has a 1-year low of $0.76 and a 1-year high of $3.62. The stock has a 50-day moving average of $1.34 and a two-hundred day moving average of $1.81.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.